Coding mutations in <i>NUS1</i> contribute to Parkinson's disease.

Abstract

Whole-exome sequencing has been successful in identifying genetic factors contributing to familial or sporadic Parkinson's disease (PD). However, this approach has not been applied to explore the impact of de novo mutations on PD pathogenesis. Here, we sequenced the exomes of 39 early onset patients, their parents, and 20 unaffected siblings to investigate the effects of de novo mutations on PD. We identified 12 genes with de novo mutations (<i>MAD1L1</i>, <i>NUP98</i>, <i>PPP2CB</i>, <i>PKMYT1</i>, <i>TRIM24</i>, <i>CEP131</i>, <i>CTTNBP2</i>, <i>NUS1</i>, <i>SMPD3</i>, <i>MGRN1</i>, <i>IFI35</i>, and <i>RUSC2</i>), which could be functionally relevant to PD pathogenesis. Further analyses of two independent case-control cohorts (1,852 patients and 1,565 controls in one cohort and 3,237 patients and 2,858 controls in the other) revealed that <i>NUS1</i> harbors significantly more rare nonsynonymous variants (<i>P</i> = 1.01E-5, odds ratio = 11.3) in PD patients than in controls. Functional studies in <i>Drosophila</i> demonstrated that the loss of <i>NUS1</i> could reduce the climbing ability, dopamine level, and number of dopaminergic neurons in 30-day-old flies and could induce apoptosis in fly brain. Together, our data suggest that de novo mutations could contribute to early onset PD pathogenesis and identify <i>NUS1</i> as a candidate gene for PD.